OnCusp Therapeutics has reported initial Phase Ia data from its Phase I trial of the CDH6-directed antibody-drug conjugate ...

DelveInsight Business Research LLP As per DelveInsight’s estimates, among the 7MM, the US captured the highest market of high- and low-grade serous ovarian cancer of nearly USD 1,900 million in ...

Drugmakers are turning to biomarkers, like folate receptor alpha, and even cell therapies to tackle this deadly cancer in new ...

Some 12% of women on the fast-track pathway were diagnosed with some kind of ovarian cancer. A total of 6.8% of fast-tracked ...

Approval was based on results of the ENGOT-ov60/GOG-3052/NCRI/RAMP 201 study-- a multicenter trial that included 57 patients with KRAS-mutated recurrent low-grade serous ovarian cancer.

Another small study found that those with low-grade ovarian cancer or serous borderline ovarian tumors who took the aromatase inhibitor drug called anastrozole had some improvement in their pain ...

and they can be used for low-grade serous carcinomas, which are another rare type of ovarian cancer and are more common in younger women.

They found serous tubal intraepithelial carcinoma (STIC), a precancerous lesion, in uterine serous carcinoma and serous ovarian carcinoma but not in nonserous uterine cancer or benign conditions.

“Today’s approval of AVMAPKI FAKZYNJA CO-PACK for patients with KRAS-mutated recurrent low-grade serous ovarian cancer represents not only the first-ever FDA-approved treatment specifically ...

The FDA approved Avmapki Fakzynja Co-pack for KRAS-mutated, recurrent, low-grade serous ovarian cancer after prior systemic therapy. The RAMP-201 trial showed a 44% response rate, with response ...

“High-grade serous ovarian carcinoma (HGSOC) is the most common ovarian cancer subtype, with more than 70% of patients presenting with metastatic disease at the time of diagnosis,” the authors ...

The study included individuals between 20 to 79 years of age who had been diagnosed with high-grade serous ovarian cancer, the most common ovarian cancer. State-of-the-art tumor sequencing ...